Neuroimmunology
Natalizumab and PML in MS
Jul. 26, 2023
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.
Incidence of progressive multifocal leukoencephalopathy (PML) by epochs of 12 infusions, compared with cumulative incidence, per 1000 natalizumab-treated patients. X-axis shows epochs of 12 infusions, or approximately one year of therapy. Polynomial curve fitting of means per epoch. Data from Biogen, January-September, 2013. (Contributed by Dr. Anthony Reder.)